前往: 導覽搜尋
Confusion grey.svg

興奮劑又稱為中樞神經興奮劑中樞神經刺激劑(英文名稱:stimulantpsycho-stimulant)是一系列精神藥物的統稱,其中包括可以增加活動力的藥物[1]、會令人感到愉快和振奮的藥物,以及有交感興奮作用的藥物[2]。興奮劑可以提升警覺心、注意力和活力,同時也增加血壓心跳呼吸[3],常用作處方藥(例如ADHD的兒童或成人[3]),但也有用於藥物治療以外的使用(可能是脫法藥物英語Legal intoxicant或是非法使用),可能做為表現增強物質英語performance-enhancing substance或是娛樂性藥物

一些藥物能影響自我管理能力。例如:歸類為中樞神經興奮劑的藥物:派醋甲酯(methylphenidate)和安非他命(amphetamine)。適度適量地使用它們能提升一個人整體的衝動控制能力(inhibitory control),且被用來治療注意力不足過動症(ADHD)患者。[4][5] 同理,中樞神經抑制劑英語depressants(depressants)(例如:酒精)由於會讓腦中神經傳導物質濃度降低、減少許多大腦區域的活性等,所以可能會造成專注力、神智清醒度等自我管理能力的下降。[6]


醫療用途(Medical uses)[編輯]

中樞神經刺激劑在醫學上用來治療肥胖睡眠疾患嗜睡症(narcolepsy)、情感性疾患注意力不足過動症頑固型憂鬱症英語treatment-resistant depression頑固型強迫症英語treatment-resistant obsessive compulsive disorder氣喘、和鼻塞等。 [3] [8]

Drugs used to treat obesity are called 降食慾藥英語Anorectic(anorectic), and generally include drugs that follow the general definition of a stimulant but other drugs such as CB1受體英語CB1 receptor(CB1 receptor)antagonists exist in this class too.[9] [10] Drugs used to treat sleep disorders such as excessive daytime sleepiness are called eugeroic英語eugeroics, and include notable stimulants such as modafinil.[11] [12] Stimulants are used in impulse control disorders such as ADHD[13] and off label in mood disorders such as major depressive disorder to increase energy, focus and elevate mood.[14] Stimulants such as epinephrine,[15] theophylline and salbutamol[16] orally have been used to treat asthma, but inhaled adrenergic drugs are now preferred due to less systemic side effects. Many drugs have historically been used to treat nasal congestion from the stimulant class, however concerns about safety and abuse potential have led to mostly the use of pseudoephedrine to treat nasal congestion.[17] [18]

Target Drug Recognition site
Amphetamine Effect on α and β receptor
Atropine M2(muscarinic) antagonist
Cocaine Dopamine transporter
Methylphenidate Dopamine receptor antagonist
Nicotine Nicotinic Ach






只要按照指示使用,中樞神經刺激劑如同其他藥品一樣安全,不會導致藥物濫用或成癮。研究顯示,以中樞神經興奮劑治療注意力不足過動症的患者,其往後將比沒有以中樞神經興奮劑治療的注意力不足過動症患者享有明顯更低的藥物濫用風險。 [3]



較常見的副作用[註 1]包含:

  • 難以入睡或難以維持睡眠。
  • 胃口降低。
  • 胃部不適。
  • 頭疼。

較少見的副作用[註 2]包含:

  • 肢體抽動或聲音抽動。(突然的、重複的動作或聲音)



  1. ^ 「常見副作用」的定義為:在臨床試驗中,實驗組中至少5 %的人出現此症狀,且在實驗組中出現此反應的比例為安慰組的兩倍。
  2. ^ 「較少見的副作用」的定義為:在臨床試驗中,實驗組中至少2 %的人出現此症狀,且在實驗組中出現此反應的比例多於安慰組。


  1. ^ stimulant - definition of stimulant in English | Oxford Dictionaries. Oxford Dictionaries | English. 
  2. ^ Treatment, Center for Substance Abuse. Chapter 2—How Stimulants Affect the Brain and Behavior. Substance Abuse and Mental Health Services Administration (US) (英語). 
  3. ^ 3.0 3.1 3.2 3.3 3.4 3.5 Mental Health Medications.. National Institute of mental health. (tertiary source). October 2016 [April 15th, 2017.]. 
  4. ^ Spencer RC, Devilbiss DM, Berridge CW. The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex. Biol. Psychiatry. June 2015, 77 (11): 940–950. PMID 25499957. doi:10.1016/j.biopsych.2014.09.013. The procognitive actions of psychostimulants are only associated with low doses. Surprisingly, despite nearly 80 years of clinical use, the neurobiology of the procognitive actions of psychostimulants has only recently been systematically investigated. Findings from this research unambiguously demonstrate that the cognition-enhancing effects of psychostimulants involve the preferential elevation of catecholamines in the PFC and the subsequent activation of norepinephrine α2 and dopamine D1 receptors. ... This differential modulation of PFC-dependent processes across dose appears to be associated with the differential involvement of noradrenergic α2 versus α1 receptors. Collectively, this evidence indicates that at low, clinically relevant doses, psychostimulants are devoid of the behavioral and neurochemical actions that define this class of drugs and instead act largely as cognitive enhancers (improving PFC-dependent function). This information has potentially important clinical implications as well as relevance for public health policy regarding the widespread clinical use of psychostimulants and for the development of novel pharmacologic treatments for attention-deficit/hyperactivity disorder and other conditions associated with PFC dysregulation. ... In particular, in both animals and humans, lower doses maximally improve performance in tests of working memory and response inhibition, whereas maximal suppression of overt behavior and facilitation of attentional processes occurs at higher doses. 
  5. ^ Ilieva IP, Hook CJ, Farah MJ. Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis. J. Cogn. Neurosci. January 2015: 1–21. PMID 25591060. doi:10.1162/jocn_a_00776. Specifically, in a set of experiments limited to high-quality designs, we found significant enhancement of several cognitive abilities. ... The results of this meta-analysis ... do confirm the reality of cognitive enhancing effects for normal healthy adults in general, while also indicating that these effects are modest in size. 
  6. ^ Long-term & Short-term effects, depressants, brand names: Foundation for a drug free work. 
  7. ^ Top 100 Drugs for Q4 2013 by Sales - U.S. Pharmaceutical Statistics. www.drugs.com. 
  8. ^ Harper, S. J.; Jones, N. S. Cocaine: what role does it have in current ENT practice? A review of the current literature. The Journal of Laryngology and Otology. 1 October 2006, 120 (10): 808–811. ISSN 1748-5460. PMID 16848922. doi:10.1017/S0022215106001459. 
  9. ^ Kaplan, Lee M. Pharmacological therapies for obesity. Gastroenterology Clinics of North America. 1 March 2005, 34 (1): 91–104. ISSN 0889-8553. PMID 15823441. doi:10.1016/j.gtc.2004.12.002. 
  10. ^ Palamara, Kerri L.; Mogul, Harriette R.; Peterson, Stephen J.; Frishman, William H. Obesity: new perspectives and pharmacotherapies. Cardiology in Review. 1 October 2016, 14 (5): 238–258. ISSN 1538-4683. PMID 16924165. doi:10.1097/01.crd.0000233903.57946.fd. 
  11. ^ The Voice of the Patient A series of reports from the U.S. Food and Drug Administration’s (FDA’s) Patient-Focused Drug Development Initiative (PDF). Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA). 
  12. ^ Heal, David J; Smith, Sharon L; Gosden, Jane; Nutt, David J. Amphetamine, past and present – a pharmacological and clinical perspective. Journal of Psychopharmacology (Oxford, England). 7 January 2017, 27 (6): 479–496. ISSN 0269-8811. PMC 3666194. doi:10.1177/0269881113482532. 
  13. ^ Research, Center for Drug Evaluation and. Drug Safety and Availability - FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. www.fda.gov (英語). 
  14. ^ Stotz, Gabriele; Woggon, Brigitte; Angst, Jules. Psychostimulants in the therapy of treatment-resistant depression Review of the literature and findings from a retrospective study in 65 depressed patients. Dialogues in Clinical Neuroscience. 1 December 1999, 1 (3): 165–174. ISSN 1294-8322. PMC 3181580. 
  15. ^ Doig RL. Epinephrin; especially in asthma. California State Journal of Medicine. February 1905, 3 (2): 54–5. PMC 1650334. PMID 18733372. 
  16. ^ Chu, Eric K.; Drazen, Jeffrey M. Asthma. American Journal of Respiratory and Critical Care Medicine. 1 June 2005, 171 (11): 1202–1208. ISSN 1073-449X. doi:10.1164/rccm.200502-257OE. 
  17. ^ Bicopoulos D,; Drug information for the healthcare professional., AusDI, 編, Castle Hill: Pharmaceutical Care Information Services 2nd edition, 2002. 
  18. ^ Pseudoephedrine (By mouth). PubMed Health. 
  19. ^ Overview of nano-enabled screening of drug-facilitated crime: A promising tool in forensic investigation